हिंदी में पढ़ें

Cipla

Cipla shares surge nearly 10% after positive USFDA update on Goa facility

Cipla shares surge nearly 10% after positive USFDA update on Goa facility

Thu, Oct 31, 2024

USFDA's VAI classification boosts Cipla’s outlook for niche drug launches, including Abraxane generic

'Diwali Offer' Stocks by Anil Singhvi: These 2 largecap, 1 smallcap scrips can give up to 70% return - Check targets

'Diwali Offer' Stocks by Anil Singhvi: These 2 largecap, 1 smallcap scrips can give up to 70% return - Check targets

Thu, Oct 31, 2024

'Diwali Offer' Stocks by Anil Singhvi: Stock markets have been very volatile in last one month. Benchmark equity indices Sensex and Nifty fell in early trade even Thursday i.e. October 31, 2024. Amid this, investors are looking for stocks that can offer good return in long term.

Cipla Q2 earnings preview: Margins under pressure as US, domestic sales outlook remains modest

Cipla Q2 earnings preview: Margins under pressure as US, domestic sales outlook remains modest

Tue, Oct 29, 2024

Zee Business forecasts indicate a three percent year-on-year revenue increase, with Cipla’s Q2 revenue expected at Rs 6,892 crore, up from Rs 6,678 crore in the same quarter last year

TRENDING NOW

'10 ki Kamai': Should you buy Cipla shares? Expert gives this target

'10 ki Kamai': Should you buy Cipla shares? Expert gives this target

Mon, May 27, 2019

Sumeet Bagadia, ED, Choice Broking told Zee Business TV, ''Cipla is looking positive for last few months. The stock has broken the 200 DMA levels and seems a decent buy for short term targets of Rs 600 and Rs 610.

Cipla Q4 net profit jumps over 2-fold to Rs 357.68 cr; to raise up to Rs 6,000 cr

Cipla Q4 net profit jumps over 2-fold to Rs 357.68 cr; to raise up to Rs 6,000 cr

Wed, May 22, 2019

For the 2018-19 fiscal, the company's net profit was Rs 1,492.44 crore as against Rs 1,416.57 crore in 2017-18. Total revenue from operations for the last fiscal stood at Rs 16,362.41 crore. It was Rs 15,219.25 crore in the preceding financial year.

Cipla to launch cinacalcet hydrochloride tablets in US.

Cipla to launch cinacalcet hydrochloride tablets in US.

Wed, Mar 06, 2019

Cipla said, its cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg) is generic therapeutic equivalent version of Sensipar, a branded drug marketed by Amgen Inc.

Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018

Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018

Mon, Dec 31, 2018

The sector has been volatile throughout the year due to constant news flow in the markets. Some giants of the sector witnessed objections over their manufacturing plants and medicine pricing in the U.S. markets.

Cipla recalls 4,800 bottles of anti-HIV tablets from US

Cipla recalls 4,800 bottles of anti-HIV tablets from US

Sun, Dec 30, 2018

As per the latest Enforcement Report by the United States Food and Drug Administration (USFDA), the reason for the recall of the bottles is 'failed dissolution specifications'.

Top 5 stocks in focus on July 12: HCL, Telecom sector to Cipla, here are the 5 newsmakers of the day

Top 5 stocks in focus on July 12: HCL, Telecom sector to Cipla, here are the 5 newsmakers of the day

Thu, Jul 12, 2018

The domestic market remained flat on July 11, 2018, as the BSE Sensex and Nifty closed in green while BankNifty depreciated by 78.35 points. But there were certain stocks that made news on the day and can have an impact on the market on July 12, 2018.

Cipla share price rallies 3% on USFDA nod to generic HIV drug

Cipla share price rallies 3% on USFDA nod to generic HIV drug

Wed, Jun 20, 2018

Cipla share price rallied over 3 per cent after the drug major received approval from the US health regulator to market Efavirenz tablets. These tablets are used to treat HIV-1 infections in adults. Reacting to the news, the stock gained as much as 3.27 per cent to Rs 622 on the BSE.

Infosys, Cipla among key stocks hogging limelight in Wednesday's trade

Infosys, Cipla among key stocks hogging limelight in Wednesday's trade

Wed, Jun 20, 2018

Overnight, US stocks fell on Tuesday as a sharp escalation in the trade dispute between the United States and China rattled markets and put the Dow Jones Industrial Average back in negative territory for the year. However, S&P 500 futures edged slightly higher, rising 0.05 per cent.

Cipla share price surges 7% on robust Q4 earnings

Cipla share price surges 7% on robust Q4 earnings

Wed, May 23, 2018

Reacting to positive earnings, the stock gained as much as 6.78 per cent to Rs 562.50 on the BSE. The scrip settled at Rs 532.75, up 1.6 per cent.

Sensex surges over 500 points; key reasons behind smart pullback today

Sensex surges over 500 points; key reasons behind smart pullback today

Thu, Feb 08, 2018

The S&P BSE Sensex rallied over 500 points intraday, snapping the seven-session long losing streak, while the broader Nifty50 also regained its crucial 10,600 mark. The Sensex, however, is still over 1800 points down from its peak 36443.98 hit on January 29, 2018.

Sensex at day's high; Cipla, PVR among key stocks buzzing today

Sensex at day's high; Cipla, PVR among key stocks buzzing today

Thu, Feb 08, 2018

The domestic market snapped its seven-session long losing streak on Thursday with the Nifty regaining its crucial 10,600 mark on the back of value-buying and as market heavyweights such as Infosys recovered and as drug maker Cipla gained on solid earnings.

Sensex climbs over 110 points after Asian uptrend

Sensex climbs over 110 points after Asian uptrend

Thu, Aug 24, 2017

dian stocks today shrugged off weakness in US markets as the Sensex surged over 110 points, with domestic investors doing the job amid positive Asian cues.

Post GST domestic pharma companies to face headwinds in 1HFY18

Post GST domestic pharma companies to face headwinds in 1HFY18

Mon, Jun 05, 2017

It has been a long and dreary quarter for pharmaceutical companies in Q4 wherein most posted a decline in net profit and things are not looking too good for the Indian pharma companies in the first half of FY18 as well.

Sensex bounces back by 195 points, Nifty rises above 9,600-mark in early trade

Sensex bounces back by 195 points, Nifty rises above 9,600-mark in early trade

Fri, Jun 02, 2017

The key equity indices of Indian markets- Sensex and Nifty- have resumed their record-setting spree and have recovered to fresh lifetime highs in opening trade on Friday on sustained buying amid positive global cues.

Higher spending, urbanisation to boost domestic pharma markets: Fitch

Higher spending, urbanisation to boost domestic pharma markets: Fitch

Tue, Nov 15, 2016

Increase in consumer spending in India would provide a boost to domestic pharmaceutical companies over the medium term, credit rating agency Fitch said.

Cipla Quality Chemical Industries plans to enter IPO market

Cipla Quality Chemical Industries plans to enter IPO market

Fri, Nov 11, 2016

Cipla said," Certain shareholders may consider selling down part or all of their stake to enable sufficient free float and liquidity.The Cipla group intends to continue holding the majority of stake and control in the subsidiary."

U.S. business rescues pharma cos in quarter one

U.S. business rescues pharma cos in quarter one

Wed, Aug 31, 2016

Following the FDC ban, this market fell by 3.9% to Rs 234 crore in the given quarter. Whereas drugs under NLEM grew by 1.6% to Rs 1061 crore, while non-NLEM drugs posted growth of 11.2% to Rs 7677 crore.

Cipla Management restructuring looks positive, analysts say

Cipla Management restructuring looks positive, analysts say

Fri, Aug 19, 2016

Last week, the company reported a 43.74% drop in consolidated net profit at Rs 365.24 crore for the quarter ended on June 30, 2016.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x